Current Report Filing (8-k)
May 05 2023 - 9:00AM
Edgar (US Regulatory)
0001739174
false
0001739174
2023-05-04
2023-05-04
0001739174
PHGE:UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember
2023-05-04
2023-05-04
0001739174
PHGE:SharesOfCommonStock0.0001ParValueMember
2023-05-04
2023-05-04
0001739174
PHGE:WarrantsEachExercisableForOnehalfOfShareOfCommonStock0.0001ParValueAtExercisePriceOf11.50PerShareMember
2023-05-04
2023-05-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 5, 2023 (May 4, 2023)
BiomX Inc. |
(Exact Name of Registrant as Specified in its Charter) |
Delaware |
|
001-38762 |
|
82-3364020 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
22 Einstein St., Floor 4
Ness
Ziona, Israel |
|
7414003 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: +972 723942377
n/a |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock |
|
PHGE.U |
|
NYSE American |
Shares of Common Stock, $0.0001 par value |
|
PHGE |
|
NYSE American |
Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share |
|
PHGE.WS |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 3.02 Unregistered Sales of Equity Securities.
As previously reported, on February 22, 2023, BiomX
Inc. (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) relating to a private
placement (the “Offering”) of an aggregate of 30,608,164 shares of the Company’s common stock (“Shares”),
including shares issuable upon the exercise of pre-funded warrants (“Pre-Funded Warrants”) to purchase additional shares
of the Company’s common stock (each, a “Security” and collectively, the “Securities”), at
a purchase price of $0.245 per Share and $0.244 per Pre-Funded Warrant.
On May 4, 2023, the
Company completed the second closing of the Offering and issued an aggregate of 24,632,243 Securities for gross proceeds of approximately
$6.0 million.
The Securities issued with
respect to the Offering are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities
Act”), pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D and Regulation S promulgated thereunder.
The Securities have not been registered under the Securities Act and may not be sold in the United States absent registration or an exemption
from registration. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall
there be any sale of the Securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOMX INC. |
|
|
|
May 5, 2023 |
By: |
/s/ Jonathan Solomon |
|
|
Name: |
Jonathan Solomon |
|
|
Title: |
Chief Executive Officer |
2
BiomX (AMEX:PHGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiomX (AMEX:PHGE)
Historical Stock Chart
From Apr 2023 to Apr 2024